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Prerequisites: First year MS biostatistics courses 
 
Description: Numerous statistical issues attendant to providing biostatistical support 
to drug research and clinical development programs are identified and 
discussed.  Real examples are used to illustrate and solidify how to 
address the issues. 
   
Required Textbook: No textbook required.  The course is presented using power points 
developed by the professor and will be provided to students on a flash 
drive 
 
Secondary Text: Peace, K.E. (Editor and author): Statistical Issues in Pharmaceutical 
Drug Development; Marcel Dekker, Inc., New York, ISBN 0-8247-
8290-9, 1990. 
 
Other Texts:                    Chen, D, Peace KE: Applied Meta-Analysis using R. Chapman &    
                                         Hall/CRC, Taylor and Francis Group; 13: 978-1-4665-0599-5; May,  
                                         2013. 
 
Chen D, Sun J, Peace KE [Editors and Author contributors]   (2012): 
Interval-Censored Time-to-Event Data: Methods and Applications"; 
Chapman & Hall/CRC, Taylor and Francis Group; Published July, 
2012. 
 
Chen D, Peace KE (2010): Clinical Trial Data Analysis using R; 
Chapman & Hall/CRC, Taylor and Francis Group; ISBN:  978-1-
4398-4020-7 
 
Peace, K. E., Chen, D (2010): Clinical Trial Methodology; Chapman 
& Hall/CRC, Taylor and Francis Group. 
 
 
Instructor:  Karl E. Peace 
Office:  1005 Hendricks Hall 
Phone:  912-478-7905 
E-Mail Address:        Peacekarl@frontier.com, kepeace@georgiasouthern.edu 
Office Hours:             Monday – 3:00 PM – 5:00 PM 
Other times by appointment; email contact is encouraged 
Class Meets:  Monday – 5:00 PM-to-7:45 PM 
    
Peace, K. E. [Editor and Author contributor] (2008): Design and 
Analysis of Clinical Trials with Time to Event Endpoints; Chapman & 
Hall/CRC Taylor and Francis Group; Boca, ISBN 978-1-4200-6639-5. 
 
Peace, K. E. [Editor and Author contributor] (1992): 
Biopharmaceutical Sequential Statistical Applications. Marcel Dekker, 
Inc., New York, ISBN 0-8247-8628-9. 
 
Peace, K.E. [Editor and author] (1988): Biopharmaceutical Statistics in 
Drug Development. Marcel Dekker, Inc., New York, ISBN 0-8247-
7798-0. 
 
Program Goals: At the completion of this program the student will be able to: 
 
 Distinguish among the different measurement scales and the 
implications for selection of statistical methods to be used based on 
these distinctions; 
 Apply descriptive techniques commonly used to summarize  health 
related data; 
 Apply common statistical methods for inference; 
 Describe preferred methodological alternatives to commonly 
used statistical methods when assumptions are not met; 
 Apply descriptive and inferential methodologies according to the 
type of study design for answering a particular research question; 
 Interpret results of statistical analyses found in health related 
studies; 
 Develop written and oral presentations based on statistical analyses 
for both health professionals and educated lay audiences; and 
 
Course Objectives:  At the completion of this course the student will have an understanding of:  
 
1. Statistical Issues in Drug Research & Development Background 
2. Constructing Statistical Hypotheses to Reflect Study Objectives 
3. P-values vs. C.I. for Statistical Inference 
4. P-Values: One-Sided or Two-Sided? 
5. Sample Size Considerations in Clinical Trials Pre-Market Approval 
6. Statistical Analysis Section of a Clinical Trial Protocol  
7. The Importance of Numbers (of Patients) in Cancer Clinical Trials 
8. The Use of the Global Null Hypothesis in Clinical Trials 
9. A. Dual Control Groups in Rodent Carcinogenicity Studies 
      B. Some Real Examples of Dual Control Groups in Rodent Carcinogenicity Studies 
10. Statistical Methods for a Three-Period Crossover Design in Which High Dose Cannot be 
Used First 
11. Active Controlled Equivalence Studies (ACES) or Non-Inferiority Trials 
12. The Use of  Placebo in Combination Drug Development 
13. Biostatistical Aspects of the Development of Anti-Anginal Drugs: a Phase II Clinical 
Trial Incorporating an Equiradial Hexagonal Design with Response Surface Methodology 
14. Intention-to-Treat in Clinical Trials 
15. Interim Analyses: p-Value and Power Computations in Multiple Look Trials 
16. The Statistical Analysis of Dose Response Studies 
17. Multiple Inferences in Clinical Trials 
18. Dosing in the Elderly 
19. The Pooling of Data from Multicentre Clinical Trials 
20. Monitoring Adverse Experiences in Clinical Drug Development 
21. Analysis and Summarization of Safety Data Collected in Clinical Trials 
22. Meta-Analysis in Ulcer Disease 
 
Overview of the Content to be Covered During the Semester: 
 
 Background 
 Constructing Statistical Hypotheses to Reflect Study Objectives 
 P-values vs. C.I. for Statistical Inference 
 P-Values: One-Sided or Two-Sided? 
 Sample Size Considerations in Clinical Trials Pre-Market Approval 
 Statistical Analysis Section of a Clinical Trial Protocol  
 The Importance of Numbers (of Patients) in Cancer Clinical Trials 
 The Use of the Global Null Hypothesis in Clinical Trials 
 A. Dual Control Groups in Rodent Carcinogenicity Studies 
B. Some Real Examples of Dual Control Groups in Rodent Carcinogenicity Studies 
 Statistical Methods for a Three-Period Crossover Design in Which High Dose Cannot be 
Used First 
 Active Controlled Equivalence Studies (ACES) or Non-Inferiority Trials 
 The Use of  Placebo in Combination Drug Development 
 Biostatistical Aspects of the Development of Anti-Anginal Drugs: a Phase II Clinical 
Trial Incorporating an Equiradial Hexagonal Design with Response Surface Methodology 
 Intention-to-Treat in Clinical Trials 
 Interim Analyses: p-Value and Power Computations in Multiple Look Trials 
 The Statistical Analysis of Dose Response Studies 
 Multiple Inferences in Clinical Trials 
 Dosing in the Elderly 
 The Pooling of Data from Multicentre Clinical Trials 
 Monitoring Adverse Experiences in Clinical Drug Development 
 Analysis and Summarization of Safety Data Collected in Clinical Trials 
 Meta-Analysis in Ulcer Disease 
 
Instructional Methods: Class meetings will be a combination of lecture and class discussion. 
Approximately half of the class meetings will be facilitated via Adobe 
Connect in real time (blended format) and the remainder physically in 
the classroom. Homework assignments, class participation and the 
final examination constitute the basis of student evaluation.   Students 
are expected to make use of office hours (in my office or via adobe 
connect) and email contact to discuss concepts or difficulties they may 
have. In addition, they may seek the assistance of the GA. 
   
 
Exam Schedule and 
Final Examination: Final Examination: Week of Finals Spring 2016 
 
Grading: Weighting of assignments for purposes of grading will be as follows: 
 
 Final Exam …….……………………. 60% 
 Assignments ……….…………………. 30% 
                                          Class Participation ………………………….      10% 
          ____ 
 Total Possible               100% 
   The following point scale will be utilized in grading: 
 
90% - 100% A 
80% -   90% B 
70% -   80% C 
60% -   70% D 
  
                                         There are times when extraordinary circumstances occur (e.g., serious 
illness, death in the family, etc.).  In such circumstances, and/or if you 
need additional time to satisfactorily complete any course requirement, 
please consult with the instructor within a reasonable amount of time.  
Nota Bene: Extensions are not guaranteed and will be granted solely at 
the discretion of the instructor. 
 
Academic Misconduct: As a student registered at this University, it is expected that you will 
adhere to only the strictest standards of conduct. Your continued 
enrollment in this course is an implied contract between you and the 
instructor on this issue; from this point forward, it is assumed that you 
will conduct yourself appropriately. 
 
Academic integrity relates to the appropriate use of intellectual 
property.  The syllabus, lecture notes, and all materials presented 
and/or distributed during this course are protected by copyright law.  
Students are authorized to take notes in class, but that authorization 
extends only to making one set of notes for personal (and no other) 
use.  As such, students are not authorized to sell, license, commercially 
publish, distribute, transmit, display, or record notes in or from class 
without the express written permission of the instructor. 
 
Attendance Policy: Federal regulations require attendance be verified prior to distribution 




One Final Note: The contents of this syllabus are as complete and accurate as possible.  
The instructor reserves the right to make any changes necessary to the 
syllabus and course material.  The instructor will make every effort to 
inform students of changes as they occur.  It is the responsibility of the 
student to know what changes have been made in order to successfully 




































Student Information  (SIDRD Class): 
 
      Print Full Name                     email address                Pledge to spend enough time                 
                                                                                         to master material? Circle one. 
 
1. ________________          ________________            Yes          No       Undecided 
 
2. ________________          ________________            Yes          No       Undecided 
  
3. ________________          ________________            Yes          No       Undecided 
 
4. ________________          ________________            Yes          No       Undecided 
 
5. ________________          ________________            Yes          No       Undecided 
 
6. ________________          ________________            Yes          No       Undecided 
 
7. ________________          ________________            Yes          No       Undecided 
 
8. ________________          ________________            Yes          No       Undecided 
 
9. ________________          ________________            Yes          No       Undecided 
 
1
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